Drug intelligence / Profile preview

WJ47156

Development stage: Phase 1
Lead developer: Junshi Biosciences
Modality: Small Molecules
Administration: Oral

Overview

WJ47156 is a targeted histone deacetylase (HDAC) inhibitor being developed for the treatment of malignant tumors. It selectively inhibits HDAC1, HDAC2, and HDAC3, and works by inducing cell cycle arrest, inhibiting angiogenesis, regulating immune response, and promoting cancer cell senescence and apoptosis. It belongs to the class of epigenetic modulator drugs and is administered orally.

Other names: WJ47156 tabletsWJ-47156 tabletsWJ 47156 tablets

Targets

HDAC1 (Histone Deacetylase 1)

Beyond the preview

Go deeper on WJ47156.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WJ47156.

Explore the full profile